Protocol V compared aflibercept, laser and observation for centre-involved diabetic macular oedema with good visual acuity. At two years, immediate injections did not reduce vision loss significantly.
doi: 10.1001/jama.2019.5790Two phase 3 trials compared faricimab with aflibercept in neovascular AMD. Faricimab produced comparable visual-acuity outcomes and allowed longer injection intervals for some patients.
doi: 10.1016/S0140-6736(22)00010-1A meta-analysis compared intravitreal ranibizumab with laser photocoagulation for diabetic macular oedema.
doi: 10.3389/fendo.2025.1608456A systematic review compared economic models for drugs used in neovascular AMD.
doi: 10.1016/j.vhri.2025.101542A meta-analysis compared aflibercept biosimilars with reference aflibercept in neovascular AMD and diabetic macular oedema.
doi: 10.1016/j.survophthal.2025.11.007PHOTON compared 8 mg aflibercept at extended intervals with standard 2 mg dosing every eight weeks.
doi: 10.1016/j.ophtha.2025.10.028The study compared volumetric intraretinal and subretinal fluid measures with conventional central retinal thickness.
doi: 10.1111/aos.70000